Document is current

Any future updates will be listed below

A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

Crossref DOI link: https://doi.org/10.1186/s40360-018-0200-y

Published Online: 2018-03-16

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark